SRSF2 and acute myeloid leukemia: Thus, one study reported in older NPM1-mut AML patients (≥75 years) a significant enrichment of TET2, SRSF2, and IDH2 mutations, with a reduced frequency of DNMT3A mutations, compared with what was observed in younger NMP1-mut AML patients (45% vs. 16%, 22% vs. 3.5%, 28% vs. 12%, and 27% vs. 52%, respectively) [18].